BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34976810)

  • 1.
    Wang T; Yue W; Tang G; Ye M; Yu J; Liu B; Jiao L; Liu X; Yin S; Chen J; Gao L; Yang J; He M
    Front Oncol; 2021; 11():763151. PubMed ID: 34976810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
    Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
    Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma.
    Merrien M; Wasik AM; Ljung E; Morsy MHA; de Matos Rodrigues J; Carlsten M; Rassidakis GZ; Christensson B; Kolstad A; Jerkeman M; Ek S; Herold N; Wahlin BE; Sander B
    Virchows Arch; 2022 Mar; 480(3):655-666. PubMed ID: 34738194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
    Morsy MHA; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
    Blood; 2024 Jan; 143(19):1953-1964. PubMed ID: 38774451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
    Abdelrazak Morsy MH; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
    Blood; 2024 May; 143(19):1953-1964. PubMed ID: 38237141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SAMHD1: To overcome multiple anti-cancer drugs resistance in hematological malignancies.
    Wang T; Liu P; Yang J
    Genes Dis; 2023 May; 10(3):891-900. PubMed ID: 37396510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
    Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
    Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of SAMHD1 and its mutation on prognosis of colon cancer.
    Zhang Z; Li P; Sun P
    Oncol Lett; 2022 Sep; 24(3):303. PubMed ID: 35949607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
    Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
    Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma.
    Knapp CM; He J; Lister J; Whitehead KA
    Exp Biol Med (Maywood); 2016 May; 241(9):1007-13. PubMed ID: 27022142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Insights into the High-efficiency Catalytic Mechanism of the Sterile α-Motif/Histidine-Aspartate Domain-containing Protein.
    Li Y; Kong J; Peng X; Hou W; Qin X; Yu XF
    J Biol Chem; 2015 Dec; 290(49):29428-37. PubMed ID: 26438820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML.
    Zhang F; Sun J; Tang X; Liang Y; Jiao Q; Yu B; Dai Z; Yuan X; Li J; Yan J; Zhang Z; Fan S; Wang M; Hu H; Zhang C; Lv XB
    Cell Death Dis; 2022 Jul; 13(7):590. PubMed ID: 35803902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
    Herold N; Rudd SG; Sanjiv K; Kutzner J; Myrberg IH; Paulin CBJ; Olsen TK; Helleday T; Henter JI; Schaller T
    Exp Hematol; 2017 Aug; 52():32-39. PubMed ID: 28502830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cyclin-Binding Motif in Human SAMHD1 Is Required for Its HIV-1 Restriction, dNTPase Activity, Tetramer Formation, and Efficient Phosphorylation.
    St Gelais C; Kim SH; Maksimova VV; Buzovetsky O; Knecht KM; Shepard C; Kim B; Xiong Y; Wu L
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29321329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis.
    Kodigepalli KM; Bonifati S; Tirumuru N; Wu L
    Cell Cycle; 2018; 17(9):1124-1137. PubMed ID: 29911928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAMHD1 host restriction factor: a link with innate immune sensing of retrovirus infection.
    Sze A; Olagnier D; Lin R; van Grevenynghe J; Hiscott J
    J Mol Biol; 2013 Dec; 425(24):4981-94. PubMed ID: 24161438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types.
    Felip E; Gutiérrez-Chamorro L; Gómez M; Garcia-Vidal E; Romeo M; Morán T; Layos L; Pérez-Roca L; Riveira-Muñoz E; Clotet B; Fernandez PL; Mesía R; Martínez-Cardús A; Ballana E; Margelí M
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells.
    Zou ZK; Huang YQ; Zou Y; Zheng XK; Ma XD
    Int J Mol Med; 2017 Aug; 40(2):319-328. PubMed ID: 28627608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
    Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
    J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.